SavedAdd your journal

Journals / İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi / 2019 / Sayı: 9

An Investigation into the Role of IGF-1 and IGFBP3 in the Diagnosis and Treatment Response in Esophageal Cancer

IGF-1 ve IGFBP3’ün Özofagus Kanseri’nin Tanı ve Tedaviye Yanıtındaki Yerinin Araştırılması

Süleyman Bademler(İSTANBUL ÜNİVERSİTESİ, İSTANBUL TIP FAKÜLTESİ)0000-0002-0221-7153
Merve Müge Üçüncü(Zeytinburnu Toplum Sağlığı Merkezi)0000-0001-6125-1848
Murat Serilmez(İSTANBUL FACULTY OF MEDICINE)0000-0001-8502-2505
Pages
852–863
Publication Date
2019-12-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In our study, it is aimed to investigate the role of IGFBP3 and IGF-1 in the early diagnosis of esophageal tumors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Esophageal cancer (EC) is the eighth most common cancer among all cancers worldwide.
📊
Key Findings & Data:It constitutes 1.5-2% of all cancers and 5-7% of gastrointestinal cancers.
💡
Conclusion & Impact:In our study, it is aimed to investigate the role of IGFBP3 and IGF-1 in the early diagnosis of esophageal tumors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Özofagus kanseri · IGF-1 seviyesi · IGFBP-3 seviyesi

Abstract

Aim: Esophageal cancer (EC) is the eighth most common cancer among all cancers worldwide. It constitutes 1.5-2% of all cancers and 5-7% of gastrointestinal cancers. Mortality reduction by early diagnosis, early treatment, and close follow-up is possible in esophageal cancer. However, reliable markers that rapidly provide results for early diagnosis are necessary in order to make such a diagnosis. In our study, it is aimed to investigate the role of IGFBP3 and IGF-1 in the early diagnosis of esophageal tumors.

Özet

Amaç: Özofagus kanseri dünya genelinde tüm kanserler arasında sekizinci sırada yer almaktadır. Tüm kanserlerin % 1,5–2'sini, sindirim sistemi kanserlerinin ise % 5-7'sini oluşturmaktadır. Bu kanser türünde erken tanı, erken tedavi ve yakın takiple mortalite azaltılabilmektedir. Ancak erken tanı konabilmesi için erken tanıda kullanılabilecek hızlı sonuç alınan, güvenilir belirteçlere ihtiyaç vardır. Çalışmamızda özofagus tümörünün erken tanısı için IGFBP3 ve IGF-1’in kullanılabilirliğini araştırmayı amaçladık.

🔖

Cite This Article

Bademler, S., Üçüncü, M. M., Serilmez, M. (2019). An Investigation into the Role of IGF-1 and IGFBP3 in the Diagnosis and Treatment Response in Esophageal Cancer. İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi, Sayı: 9, 852–863. https://doi.org/10.38079/igusabder.586721

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (20)

  1. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400-412. doi: 10.1016/S0140-6736(12)60643-6
  2. National Cancer Insti¬tute. SEER Cancer Statistics Review, 1975-2013. Based on November 2015 SEER data submission, posted to the SEER website, April 2016. https://seer.cancer.gov/archive/csr/1975_2013/ Accessed September 21, 2018
  3. Short MW, Burgers KG, Fry VT. Esophageal cancer. American Family Physician. 2017;95(1):22-28. PMID: 28075104
  4. Rahman OA. Insulin-like growth factor pathway aberrations and gastriccancer; evaluation of prognostic significance and assessmentof therapeutic potentials. Medical Oncology. 2015;32(1):431. doi: 10.1007/s12032-014-0431-8
  5. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. The Lancet Oncology. 2002;3(5):298-302
  6. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nature Reviews Cancer. 2004;4(7):505–518. doi: 10.1038/nrc1387
  7. Bademler S, Sarı M, Üçüncü MZ, Serilmez M, Karabulut S. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth binding protein-3 (IGFBP-3) in patients with gastric cancer. Acta Medica Mediterranea. 2018;34:2055-2061 doi: 10.19193/0393-6384_2018_6_320
  8. Bademler S, Zırtıloğlu A, Sarı M, Yasasever CT, Karabulut S. IGF-1 AND IGFBP-3 in colorectal cancer, an observational case-control study. Acta Medica Mediterranea. 2019;35:15-21. doi: 10.19193/0393-6384_2019_1_1
  9. Li H, Batth IS, Qu X, et al. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGFIR therapy: overview and new insights. Molecular Cancer. 2017;16(1):6 doi: 10.1186/s12943-016-0576-5
  10. Miller BS, Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Research. 2005;65(22):10123–7. doi: 10.1158/0008-5472.CAN-05-2752
  11. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. CA Cancer Journal for Clinicians. 2012;65(2):87-108. doi: 10.3322/caac.21262
  12. Varghese TK Jr, Hofstetter WL, Rizk NP, et al. The Society of Thoracic Surgeons guidelines on the diagnosis and staging of patients with esophageal cancer. Annals of Thoracic Surgery. 2013;96(1):346-56. doi: 10.1016/j.athoracsur.2013.02.069
  13. Ajani JA, D'Amico TA, Almhanna K, et al. National comprehensive cancer network. Esophageal and esophagogastric junction cancers, version 1.2015. Journal of The National Comprhensive Cancer Network. 2015;13(2):194-227. doi:10.6004/jnccn.2015.0028
  14. Rustgi AK, El-Serag HB. Esophageal carcinoma. The New England Journal of Medicine. 2014;371:2499-2509. doi: 10.1056/NEJMra1314530
  15. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Annals of Surgical Oncology. 2010;17(7):1721-4. doi: 10.1245/s10434-010-1024-1.
  16. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63(1):7-42. doi: 10.1136/gutjnl-2013-305372.
  17. Smithers BM, Gotley DC, Martin I, Thomas JM. Comparison of the outcomes between open and minimally invasive esophagectomy. Annals of Surgery. 2007;245(2):232–240. doi: 10.1097/01.sla.0000225093.58071.c6
  18. Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Molecular Pathology. 2001;54(3):145–148. doi: 10.1136/mp.54.3.145
  19. Adachi Y, Nojima M, Mori M, et al. Insulin-like growth factor-1, IGF binding protein-3, and the risk of esophageal cancer in a nested case-control study. World Journal of Gastroenteroly. 2017;23(19):3488-3495. doi: 10.3748/wjg.v23.i19.3488
  20. Li J, Wang A, Song L, Zhao J. Expressıon and clinical significance Of AEG-1, E-Ca And IGFBP-3 in esophageal cancer patients. Acta Medica Mediterranea, 2018;34:1671. doi: 10.19193/0393-6384_2018_6_256